Reich Siegfried 4
4 · Turning Point Therapeutics, Inc. · Filed Feb 11, 2022
Insider Transaction Report
Form 4
Reich Siegfried
EVP & Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-02-09$36.30/sh−397$14,411→ 3,448 total - Award
Common Stock
2022-02-09+13,567→ 17,015 total - Award
Stock Option (right to buy)
2022-02-09+48,833→ 48,833 totalExercise: $37.68Exp: 2032-02-08→ Common Stock (48,833 underlying)
Footnotes (3)
- [F1]Sale of shares of common stock to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to Reporting Person on February 8, 2021.
- [F2]Represents restricted stock unit award granted under the Issuer's 2019 Equity Plan.
- [F3]1/48th of the shares vest monthly following February 9, 2022.